Tbio TBP TATA-box-binding protein

Protein Summary

Description

General transcription factor that functions at the core of the DNA-binding multiprotein factor TFIID (PubMed:2374612, PubMed:2363050, PubMed:2194289, PubMed:9836642, PubMed:27193682). Binding of TFIID to the TATA box is the initial transcriptional step of the pre-initiation complex (PIC), playing a role in the activation of eukaryotic genes transcribed by RNA polymerase II (PubMed:2374612, PubMed:2363050, PubMed:2194289, PubMed:9836642, PubMed:27193682). Component of a BRF2-containing transcription factor complex that regulates transcription mediated by RNA polymerase III (PubMed:26638071). Component of the transcription factor SL1/TIF-IB complex, which is involved in the assembly of the PIC (pre-initiation complex) during RNA polymerase I-dependent transcription (PubMed:15970593). The rate of PIC formation probably is primarily dependent on the rate of association of SL1 with the rDNA promoter. SL1 is involved in stabilization of nucleolar transcription factor 1/UBTF on rDNA. Initiation of transcription by RNA polymerase II requires the activities of more than 70 polypeptides. The protein that coordinates these activities is transcription factor IID (TFIID), which binds to the core promoter to position the polymerase properly, serves as the scaffold for assembly of the remainder of the transcription complex, and acts as a channel for regulatory signals. TFIID is composed of the TATA-binding protein (TBP) and a group of evolutionarily conserved proteins known as TBP-associated factors or TAFs. TAFs may participate in basal transcription, serve as coactivators, function in promoter recognition or modify general transcription factors (GTFs) to facilitate complex assembly and transcription initiation. This gene encodes TBP, the TATA-binding protein. A distinctive feature of TBP is a long string of glutamines in the N-terminus. This region of the protein modulates the DNA binding activity of the C terminus, and modulation of DNA binding affects the rate of transcription complex formation and initiation of transcription. The number of CAG repeats encoding the polyglutamine tract is usually 25-42, and expansion of the number of repeats to 45-66 increases the length of the polyglutamine string and is associated with spinocerebellar ataxia 17, a neurodegenerative disorder classified as a polyglutamine disease. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2016]

Uniprot Accession IDs

• P20226
• B4E3B3
• F5H869
• Q16845
• Q6IBM6
• Q9UC02

Gene Name

• TBP

Ensembl ID

• ENST00000230354
• ENSP00000230354
• ENSG00000112592
• ENST00000392092
• ENSP00000375942
• ENST00000540980
• ENSP00000442132

Symbol

• GTF2D1
• TF2D
• TFIID
• HDL4
• GTF2D
• SCA17
• TFIID
• GTF2D1

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
viral protein	1
virus	1
hub protein	0.99
cellular component	0.93
transcription factor binding site profile	0.92

Protein Classes

PANTHER Classes

Protein / Transcription Factor / Tata-binding Transcription Factor / Tata-box-binding Protein

Protein / Nucleic Acid Binding / Tata-box-binding Protein

DTO Classes

Protein / Transcription Factor / Tata-binding Transcription Factor / Tata-box-binding Protein

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 3387.94   (req: < 5)

Gene RIFs: 107   (req: <= 3)

Antibodies: 541   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 3387.94   (req: >= 5)

Gene RIFs: 107   (req: > 3)

Antibodies: 541   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 29

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0